explore -WSS

explore

author：comprehensive 2025-08-23 18:37:26 - browse：34

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

explore

WSS

Senate panel clears PBM, hopsital reforms

The new shift in health care is toward less care

Judge agrees to delay next hearing in Trump classified documents case

Judge agrees to delay next hearing in Trump classified documents case

10 million people disenrolled from Medicaid over past six months

10 million people disenrolled from Medicaid over past six months

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Novavax promises a turnaround & Lilly roils the obesity market

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

FDA approval of Sarepta Duchenne genetic therapy gives me hope

White House calls on federal agencies to crack down on AI abuses

Activists slam private health insurers over coverage restrictions

Abortion clinic in Cancun will cater to Americans

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Abortion clinic in Cancun will cater to Americans

explore

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

Will General Catalyst be the first of many hospital takeovers?

FDA approves Recor Medical high blood pressure device

Biden’s NIH nominee is languishing in Congress

Wisconsin governor employs partial veto to fund schools for 4 centuries

Wikipedia

explore

Wikipedia

focus